Sanjay Shukla, President and CEO, discusses changes in analyzing steroid reduction, high interest in the Expanded Access Program, and the statistical plan. The trial design considers patients mid-taper at week 48, with expectations for positive interim data in scleroderma ILD study.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing